• 1
    Delvaux M. Functional bowel disorders and irritable bowel syndrome in Europe. Aliment Pharmacol Ther 2003; 18 (Suppl. 3): 759.
  • 2
    Desai D, Faubion WA, Sandborn WJ. Review article: Biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007; 25: 24755.
  • 3
    Levay PF, Viljoen M. Lactoferrin: a general review. Haematologica 1995; 80: 25667.
  • 4
    Akin DT, Lu MQ, Lu SJ, Kendall S, Rundegren J, Arnold RR. Bactericidal activity of different forms of lactoferrin. Adv Exp Med Biol 1994; 357: 6170.
  • 5
    Guerrant RL, Araujo V, Soares E, et al. Measurement of fecal lactoferrin as a marker of fecal leukocytes. J Clin Microbiol 1992; 30: 123842.
  • 6
    Andersson KB, Sletten K, Berntzen HB, et al. The leucocyte L1 protein: identity with the cystic fibrosis antigen and the calcium-binding MRP-8 and MRP-14 macrophage components. Scand J Immunol 1988; 28: 2415.
  • 7
    Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human Peyer’s patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993; 34: 135763.
  • 8
    Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999; 34: 504.
  • 9
    Klass HJ, Neale G. Serum and faecal lysozyme in inflammatory bowel disease. Gut 1978; 19: 2339.
  • 10
    Dwarakanath AD, Finnie IA, Beesley CM, et al. Differential excretion of leucocyte granule components in inflammatory bowel disease: implications for pathogenesis. Clin Sci (Lond) 1997; 92: 30713.
  • 11
    Adeyemi EO, Hodgson HJ. Faecal elastase reflects disease activity in active ulcerative colitis. Scand J Gastroenterol 1992; 27: 13942.
  • 12
    Braegger CP, Nicholls S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 339: 8991.
  • 13
    De Jong NSH, Leach ST, Day AS. Fecal S100A12: a novel non-invasive marker in children with Crohn’s disease. Inflamm Bowel Dis 2006; 12: 56672.
  • 14
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45 (Suppl. 2): II437.
  • 15
    Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70: 43944.
  • 16
    Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial. BMJ 1989; 298: 826.
  • 17
    Gasche C, Scholmerich J, Brynskov J, et al. A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000; 6: 815.
  • 18
    Silberer H, Kuppers B, Mickisch O, et al. H. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005; 51: 11726.
  • 19
    Langhorst J, Elsenbruch S, Mueller T, et al. Comparison of 4 neutrophil-derived proteins in feces as indicators of disease activity in ulcerative colitis. Inflamm Bowel Dis 2005; 11: 108591.
  • 20
    Von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102: 80313.
    Direct Link:
  • 21
    Tibble JA, Sigthorsson G, Foster R, Forgacs I, Bjarnason I. Use of surrogate markers of inflammation and Rome criteria to distinguish organic from nonorganic intestinal disease. Gastroenterology 2002; 123: 45060.
  • 22
    Kane SV, Sandborn WJ, Rufo PA, et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 130914.
    Direct Link:
  • 23
    Fine KD, Ogunji F, George J, Niehaus MD, Guerrant RL. Utility of a rapid fecal latex agglutination test detecting the neutrophil protein, lactoferrin, for diagnosing inflammatory causes of chronic diarrhea. Am J Gastroenterol 1998; 93: 13005.
    Direct Link:
  • 24
    Sugi KSO, Hiarata I, Katsu K. Faecal lactoferrin as a marker of disease activity in inflammatory bowel disease: comparison with other neutrophil derived proteins. Am J Gastroenterol 1996; 91: 92734.
  • 25
    Bunn SK, Bisset WM, Main MJ, Golden BE. Fecal calprotectin as a measure of disease activity in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2001; 32: 1717.
  • 26
    Roseth AG, Aadland E, Jahnsen J, Raknerud N. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 17680.
  • 27
    Limburg PJ, Ahlquist DA, Sandborn WJ, et al. Fecal calprotectin levels predict colorectal inflammation among patients with chronic diarrhea referred for colonoscopy. Am J Gastroenterol 2000; 95: 28317.
    Direct Link:
  • 28
    Walker TR, Land ML, Kartashov A, et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 41422.